12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xeomin: Phase III data

In a European Phase III trial in 148 patients, caregivers gave a good or very good efficacy rating to 62% of patients receiving NT-201 vs. 33% of patients receiving placebo. Pooled...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >